The biopharma company Aegerion Pharmaceuticals Inc. has been hit by big sell-offs this week, The Wall Street Journal’s Market Watch column reports. But “it was unclear what drove the drop.” On Wednesday, the stock fell 10 percent. “It may be that investors are concerned about another shortfall in earnings,” the column speculated. The stock was above $80 after Aegerion posted quarterly earnings, as the market anticipated high sales for its Juxtapid cholesterol drug. Full story for BostonGlobe.com subscribers.
This is a summary. To read the whole story subscribe to BostonGlobe.com
© Copyright 2013 Globe Newspaper Company.
Get the full story with unlimited access to BostonGlobe.com. Just 99¢ for 4 weeks.